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Plasmablastic lymphoma (PBL) is a rare aggressive non-Hodgkin lymphoma, frequently involving the jaw
and oral mucosa in human immunodeﬁciency virus (HIV)-positive patients and is also often associated
with EpsteineBarr virus infection, occurring mostly in men. However, a number of cases have been
reported in extraoral sites and in immunocompetent patients.
There have been no reported cases of PBL without immunodeﬁciency disease from Saudi Arabia
presented by extensive cutaneous involvement. Here, we report a rare case of PBL in a 20-year-old man
without immunodeﬁciency diseases, HIV negative, and presenting with generalized extensive cutaneous
nodules as a ﬁrst presentation due to inﬁltration by neoplastic cells.
Copyright © 2016, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Plasmablastic lymphoma (PBL) is an aggressive subtype of non-
Hodgkin lymphoma (NHL), which frequently arises in the oral
cavity of human immunodeﬁciency virus (HIV)-infected patients.1,2
PBLwas ﬁrst reported in 1997 by Delecluse and colleagues,1 who
described a series of 16 diffuse large B-cell lymphomas of the oral
cavity occurring in the clinical setting of HIV and latent Eps-
teineBarr virus (EBV) infection with unique immunohistochemical
features.
PBL presents with diffuse proliferation of large neoplastic cells
resembling B-immunoblasts/plasmablasts, or plasmacytic features
with an immunophenotype of plasma cells.3
HIV-negative PBL has not been extensively reported and due to
the rarity of this disease, the natural history of PBL in HIV-negative
patients is much less understood.4 A number of cases have been
reported in extraoral sites, including the maxillary sinus, naso-
pharynx, stomach, small bowel, anus, lung, skin, soft tissues, heart,no ﬁnancial or non-ﬁnancial
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t and literature review, Dermand the spermatic cord.5,6 Furthermore, several cases of primarily
nodal PBL have also been described. PBL with cutaneous presen-
tation has also been reported.6e8
Here, we report a rare case of PBL in a 20-year-old man without
immunodeﬁciency diseases, HIV negative, and presenting with
generalized extensive cutaneous nodules with generalized
lymphadenopathy as a result of inﬁltration by neoplastic cells
which may be the ﬁrst case report of this presentation.Case Report
A 20-year-old man with no medical illnesses presented to our
hospital complaining of multiple swellings in the anterior chest
wall which had progressively increased in size. This was associated
with an on-and-off fever, night sweats, and anorexia with more
than a 10-kg loss of weight over the previous 3 months. Similar
lesions appeared in the back, forearm, posterior neck, and axilla.
Two weeks prior to admission, the patient developed swelling of
the right eye, progressively increasing in size with diplopia.
On admission the patient had a temperature of 36.7C, blood
pressure of 100/60 mmHg, pulse 120 beats/min, and a respiratory
rate of 20 breaths/min. O2 saturation was 96% in room air. He had
right eye proptosis with ecchymosis and blurring of vision. He had
anterior and posterior chest wall, thigh, neck, left forearm, and
antecubical fossa skin lesions that were rubbery in consistency,er Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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had bilateral cervical, right supraclavicular, bilateral axillary, and
inguinal lymphadenopathy measuring approximately 4 cm  3 cm,
smooth, rubbery, and mobile with intact skin. He also had hepa-
tomegaly 12 cm below the costal margin, smooth, rubbery, non-
tender with a blunted edge, with no rub or murmur. The patient
was noted to have right face paresthesia involving the right fore-
head and cheek involving the ﬁfth nerve.
Other relevant investigations included a white blood cell count
of 6.3  109/L, hemoglobin 9.5 g/dL, platelets 777  109/L, lactate
dehydrogenase 12,040 U/L, C-reactive protein 176 mg/L, and
normal liver and coagulation proﬁle except for serum aspartate
transaminase enzymewhichwas 139 U/L. Viral screenwas negative
for HIV, hepatitis B and C virus, cytomegalovirus, and EBV. A
monoclonal band was observed in the gamma region with an
immunoglobulin (Ig) A level of 17.3 g/L (normal: 0.5e3 g/L) and
normal IgG and IgM levels. Therewas an increase in urine protein of
0.54 g/d (normal: 0e0.15 g/d) and a ferritin level of 1567 mg/L.
Computed tomography ﬁndings for the brain showed soft tissue
lesions within the right orbit involving the retrobulbar fat super-
omedially and along the optic nerve. A soft tissue mass was also
identiﬁed in the right paracavernous region. Computed tomogra-
phy for the chest, abdomen, and pelvis showed extensive medias-
tinal, cervical, axillary, and paratracheal lymphadenopathy.
Multiple subcutaneous enhancing solid nodules were noted at the
nape of the neck and lower down at the supraclavicular region
bilaterally. Also, there were multiple liver masses; the largest
measuring 15.8 cm. Para-aortic iliac and inguinal lymphadenopathy
was also noted together with multiple solid abdominal masses.
Inguinal lymph node biopsy and biopsy from skin lesions were
performed; the reports were delivered after 7 days (as it demanded
much work to reach a ﬁnal diagnosis).
During that time the patient's condition was deteriorating. The
patient was started on allopurinol and then rasbiuricase, and as a
monoclonal bandwas observed, the patient was started empirically
on bortezomib 1.3mg/m2 planned for doses on day of 1, 4, 8 and day
11 together with dexamethasone 8 mg three times daily. As the
patient's condition was progressing, the dexamethasone dose was
increased to 20 mg twice daily; however, the patient experienced
an abnormal behavior pattern, thus dexamethasone was held forFigure 1 Extensive subcutaneous nodules in the (A)
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lactate dehydrogenase level > 15,000 U/L, ﬁbrinogen dropping from
3 g/L at admission to 1.2 g/L, and an international normalized ratio
and activated partial thromboplastin time starting to prolong,
suggestive of a possible starting picture of disseminated intravas-
cular coagulopathy. The patient received a dose of cyclophospha-
mide 750 mg in total, and dexamethasone was resumed at a low
dose of 8 mg three times daily.
Lymph node and skin lesions were reported as plasmablastic
lymphoma. Lymph node and skin lesion immunohistochemistry
(IHC) showed positivity for CD45 (100%), IgA, CD10, Lambda, CD38,
CD138, epithelial membrane antigen, and multiple myeloma onco-
gene 1, with weak focal staining for Paired Box 5 (PAX-5) and >80%
of cells were Ki-67 positive. Negative markers include: CD2, CD3,
CD4, CD8, CD7, CD19, CD20, CD79a, CD5, CD117, CD56, CD23, Alk
protein, CD30, bcl-2, bcl-6, and kappa light chain. No evidence of
human herpesvirus 8 (HHV8) and MYC were detected by IHC. Also,
EBV was assessed for EBV-latent membrane protein 1 by IHC and
was negative (Figures 2e4).
Bone marrow aspirate and biopsy were performed and showed
hypercellular with depressed erythropoiesis and granulopoiesis
and megakaryocytic hyperplasia. The striking ﬁnding in bone
marrow was inﬁltration by abnormal medium to large cells with
rounded nuclei, prominent nucleoli, and abundant basophilic
cytoplasmic resembling immunoblast with plasmacytic differenti-
ation. Flow cytometry analysis showed these abnormal cells were
positive for CD45 (weak), CD10, CD38, CD138, and lambda light
chain restriction, and negative for CD34, human leukocyte antigen-
antigen D related, CD19, CD20, CD56, CD117, Sig, and CD58, and T-
cell and myeloid markers were also negative. Unfortunately, the
patient's condition rapidly deteriorated and he died 1 week after
diagnosis.Discussion
PBL is a rare and aggressive type of NHL that is strongly associated
with HIV infection and often occurs within the oral cavity.1,9 HIV-
related lymphomas are frequently associated with EBV. Dual
infection with EBV and HHV8 has been demonstrated in PBL.10
Cases of PBL occurring in immunocompetent patients have beenanterior and (B) posterior chest wall and neck.
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Figure 2 Low power hematoxylin and eosin magniﬁcation showing (A) deep cutaneous dense inﬁltration by malignant cells which (B) stain positive for CD45.
Figure 3 High power magniﬁcation of (A) deep cutaneous dense inﬁltrate of large cells seen mainly around the hair follicle which (B) stain positive for CD138.
Figure 4 The tumor cells show (A) negativity to EpsteineBarr virus latent membrane protein 1 and (B) strong positivity to multiple myeloma oncogene 1 by immunohistological
staining. Magniﬁcation 4.
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negative patients.4,11,12
The median age of PBL at presentation is around 50 years old,
with a male predominance of 5.7:1.3,13,14 Our patient was a young
man who presented in his 2nd decade of life, defying the average
statistics, with multiple lesions in the skin and had systemic
involvement at diagnosis. He was immunocompetent and HIV-
negative. Also, EBV and HHV8 were negative with no previous
relevant medical history or immunosuppression.Please cite this article in press as: Al Mussaed E, Generalized extensive cu
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and at extraoral sites, accurate diagnosis of such cases is not easy as
PBL may be poorly recognized by pathologists, which is partly
attributable to its relatively rare occurrence, unusual immuno-
phenotype, its heterogeneous presentation, and similarity to
different malignancies based on morphology and even immuno-
phenotypic expression.14,15
Immunophenotyping is an important adjunct in differentiating
PBL from other neoplasms. Differential diagnoses of PBLs based on ataneous nodules as a ﬁrst presentation of plasmablastic lymphoma in
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anaplastic large cell lymphoma, immunoblastic variant of diffuse
large B-cell lymphoma including primary cutaneous diffuse large B-
cell lymphoma, anaplastic plasmacytoma, myeloid sarcoma, and
metastatic melanoma. Carcinomas can be differentiated from PBLs
based on positivity for cytokeratin. Anaplastic large cell lymphomas
are negative for CD38 or CD138; PBLs are negative for CD20, while
immunoblastic variants of diffuse large B-cell lymphoma are
negative for CD138 and positive for CD20/PAX5. Myeloperoxidase
and S-100 negativity rule out myeloid sarcoma and metastatic
melanoma, respectively.2,16,17
Clinical correlation is occasionally required in the differential
diagnosis of PBL and plasma cell myeloma with plasmablastic fea-
tures because of their nearly identical immunophenotypic pro-
ﬁles.18,19 PBL is composed almost entirely of blasts, whereas
plasmacytoma typically consists of mature plasma cells, and in
addition, the extremely high proliferation rate of PBL with many
mitotic ﬁgures are unusual for plasmacytoma.20 Cytoplasmic Igs are
not detected in approximately 50% of PBL cases and, thus, the
negative staining for kappa and lambda light chains do not pre-
clude the diagnosis of PBL.20
To date, 26 cases of PBL presenting in the skin have been re-
ported; 14 cases were HIV positive, eight cases were post-
transplantation, one patient had an autoimmune disorder, while
three patients were immunocompetent without any history of
immunosuppression similar to our patient,17 but in contrast to our
patient who was young (20 years old). These three patients con-
sisted of an 80-year-old man,21 an 86-year-old woman,2 and a 62-
year-old woman.17
To the best of our knowledge, our patient represents the fourth
reported case of cutaneous PBL in an immunocompetent patient. It
can also be considered as the ﬁrst report on a patient of young age
compared with previously reported cases.
Several adverse prognostic factors have been identiﬁed,
including HIV-negativity, MYC gene rearrangement, and high-risk
international prognostic index. The outcome with available ther-
apy is poor, with median survival of <1 year; some data suggest a
better outcome of PBL if consolidation with autologous hemato-
poietic cell transplantation is used in a ﬁrst-line setting.22 Our
patient's condition rapidly deteriorated and he died 1 week after
diagnosis despite being started empirically on bortezomib together
with dexamethasone before ﬁnal diagnosis. This in contrast to
recently published cases which showed that bortezomib has shown
promising results in PBL.12
PBL is a distinct type of NHL, that most frequently affects the
oral tissue of HIV-positive patients and that usually behaves
very aggressively. Both its clinical and histopathological features
are frequently ambiguous, thus rendering the correct diagnosis
quite difﬁcult in the absence of an exhaustive integration of
clinical, morphological, phenotypic, and molecular features. The
diagnosis of such a neoplasm might be even more challenging inPlease cite this article in press as: Al Mussaed E, Generalized extensive cu
an immunocompetent patient: A case report and literature review, Dermthe setting of extraoral localizations and in immunocompetent
patients.
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